Clinical trial NCT03260023: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Official title: A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: HPV-Related Carcinoma
HPV-Related Cervical Carcinoma
HPV-Related Anal Squamous Cell Carcinoma
HPV-Related Penile Squamous Cell Carcinoma
HPV-Related Vulvar Squamous Cell Carcinoma
Keywords: Avelumab
Cancer
Anti PD-L1
Therapeutic Vaccine
Lead sponsor: Transgene
Sponsor class: INDUSTRY
Collaborators: name: Merck KGaA, Darmstadt, Germany
name: EMD Serono Research & Development Institute, Inc.
name: Pfizer
First posted: 2017-08-24
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will consist of two parts :

In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-patient dose escalation.

In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of patients with recurrent or metastatic HPV-16 positive advanced malignancies.

In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies.

In both phases, tumor response will be evaluated on local assessment using RECIST 1.1.

All patients will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.


Eligibility criteria: Inclusion Criteria:

* Female or male patients, aged at least 18 years (no upper limit of age)
* ECOG PS 0 or 1
* Life expectancy of at least 3 months
* Patients with histologically or cytologically documented metastatic or refractory/recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal.
* Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression
* Prior therapy:

  * No more than one prior systemic treatment for recurrent /metastatic disease
  * Prior treatment for recurrent or metastatic disease is not required for:

    * Patients with recurrence/progression within 6 months after completion of prior multimodal therapy for localized or locally advanced disease
    * Patients who are unsuitable for platinum-based therapy
    * Patients who refuse chemotherapy or other standard therapies for the treatment of metastatic or recurrent disease
* Limited hepatic disease for patients with liver metastases at baseline
* Availability of tumor tissue from biopsy
* At least one measurable lesion by CT scan according to RECIST 1.1.
* Adequate hematological, hepatic and renal function
* Negative blood pregnancy test at screening for women of childbearing potential
* Highly effective contraception for both male and female patients if the risk of conception exists during the study period and for 3 months after the last study treatment administration

Exclusion Criteria:

* Prior exposure to cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)
* Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with the exception of patients with adrenal insufficiency who may continue corticosteroids at physiological replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal systemic effect (topical, inhalation) are allowed
* Patients with CNS metastases except those with brain metastases treated locally and clinically stable during 4 weeks prior to start of study treatment, and those without ongoing neurological symptoms that are related to the brain localization of the disease
* Other active malignancy requiring concurrent systemic intervention
* Patients with previous malignancies other than the target malignancy to be investigated in this trial (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
* Patient with any organ transplantation, including allogeneic stem cell transplantation
* Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC), any history of anaphylaxis, or uncontrolled asthma
* Any known allergy or reaction to eggs, gentamycin or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products
* Any known allergy or reaction to any component of anti-PD-L1/PD-1 or its excipients
* Patients with known history or any evidence of active interstitial lung disease / pneumonitis
* Patients with active, known, or suspected auto-immune disease or immunodeficiency, except type I diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment
* Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction (\< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication/active intervention, history of myocarditis
* History of uncontrolled intercurrent illness including but not limited to:

  * Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mmHg or lower)
  * Uncontrolled diabetes (e.g., hemoglobin A1c ≥ 8%)
  * Uncontrolled infection

Primary outcomes:
measure: Phase Ib: To evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies
timeFrame: Day 28
measure: Phase II part 1: Overall Response Rate (ORR) by RECIST 1.1
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
measure: Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
Secondary outcomes:
measure: Overall Response Rate (ORR) by using RECIST 1.1 (phase Ib, phase II part 2)
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
measure: Progression Free Survival (PFS) (phase Ib, Phase II part 1)
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
measure: Overall Survival (OS)
timeFrame: Every 3 months and up to 3 years
measure: Duration of overall Response (DoR)
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
measure: Disease control rate (DCR)
timeFrame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
measure: Incidence of Adverse Event reported per CTCAE v4.03
timeFrame: up to 90 days after last study treatment administration
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Angers
country: France
facility: I.C.O. Paul Papin
city: Besançon
country: France
facility: CHU Besançon
city: Bordeaux
country: France
facility: Hôpital Saint André - CHU de Bordeaux
city: Colmar
country: France
facility: Hôpitaux Civils de Colmar - Hôpital Pasteur
city: Dijon
country: France
facility: CLCC Georges-François Leclerc
city: Lyon
country: France
facility: Centre Léon Bérard
city: Marseille
country: France
facility: Hopital de la Timone
city: Paris
country: France
facility: Institut Curie
city: Saint-Herblain
country: France
facility: I.C.O. Gauducheau
city: Strasbourg
country: France
facility: Centre Paul Strauss - ICANS - Institut de cancérologie Strasbourg Europe
city: Toulouse
country: France
facility: Institut Claudius Regaud - IUCT - Oncopole
city: Villejuif
country: France
facility: Institut Gustave Roussy
city: Badalona
country: Spain
facility: ICO Badalona - Hospital Germans Trias i Pujol
city: Granada
country: Spain
facility: Hospital Virgen de las Nieves
city: Madrid
country: Spain
facility: Fundación de Investigación biomédica H. 12 de Octubre
city: Madrid
country: Spain
facility: Fundación de Investigación Biomédica Hospital Clínico San Carlos
city: Malaga
country: Spain
facility: Hospital Virgen de La Victoria
city: Valencia
country: Spain
facility: Hospital General de Valencia
Study officials:
References: